A deeper understanding of the communication inside the body when someone is going through opioid withdrawal has led to a new clinical trial at the University of Calgary.
"I don't think I've had a day in clinic in the last five years where I haven't had a patient tell me they want to reduce the opioids they are taking," says Dr. Lori Montgomery, MD'03, pain clinician and clinical lead for an opioid tapering study. "The problem is there are limited options to support them, and the withdrawal symptoms can be crippling."
Trang's lab studies how opioids affect key pain centres in the nervous system.
Montgomery, an associate professor at the Cumming School of Medicine (CSM), is recruiting people for a clinical trial using a safe, well tolerated drug for gout, probenecid, to help with the disabling symptoms of opioid withdrawal.
